Biotechs request money for COVID therapeutics
German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1324 entries already.
German biotech companies and their industry association BIO Deutschland have called for appropriate investments into clinical COVID-19 therapies.
Swiss auto-immunity specialist Polyneuron Pharmaceuticals AG has received CHF14m from HBM Healthcare Investments.
Polish Mabion SA and Australian Vaxine Pty Ltd to develop Covax-19
RNA therapeutics specialist MiNA Therapeutics plc has secured £23m in a Series A financing to push development its first-in-class small activating RNA (saRNA) candidates.
Nine CEOs of COVID-19 vaccines have assured that safety of vaccinated individuals remains their top priority in development of the first COVID-19 vaccines.
The European Investment Bank has lend up to 10m to Polish microbial diagnostics specialist Scope Fluidics AS.
Roche has announced to launch a SARS-CoV-2 point-of-care antigen test this month co-developed with SD Biosensor Inc. (South Korea).
Unilever has announced to invest 1bn globally to eliminate fossil fuels as a source of carbon in its cleaning products by 2030.
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.